Loading
A phase 3 trial of Pucotenlimab, run by Taizhou Hanzhong biomedical co. LTD in colorectal cancer, active.
A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer is a phase 3 interventional study registered as NCT05652894 by Taizhou Hanzhong biomedical co. LTD, with 190 participants planned, started 2023-02-28. Conditions listed: Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.
Shares Pucotenlimab, Immune checkpoint inhibitors.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer, Immune checkpoint inhibitors.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer, Immune checkpoint inhibitors.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer, Immune checkpoint inhibitors.
Shares Pucotenlimab, Immune checkpoint inhibitors.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer, Immune checkpoint inhibitors.
Shares Pucotenlimab, Immune checkpoint inhibitors.